3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
5
Mouth Neoplasms
4
Leukoplakia, Oral
3
Erythroplasia
3
Thyroid Nodule
2
Thyroid Neoplasms
2
Thyroid Diseases
2
Insulin Resistance
2
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoid Interstitial Pneumonia
1
Leukoplakia
1
Laryngeal Diseases
1
Hyperplasia
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Squamous Cell Cancer
1
Endometrial Neoplasms
1
Diabetes Mellitus, Type 2
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Breast Diseases
1
Adenocarcinoma Of Esophagus
1
Interventions
Cisplatin
4
pembrolizumab
3
selpercatinib
2
pralsetinib
2
Pemetrexed
2
Paclitaxel
2
Fulvestrant
2
Carboplatin
2
trametinib
1
ribociclib
1
repotrectinib
1
patritumab
1
palbociclib
1
golotimod
1
exemestane
1
dabrafenib
1
cobimetinib
1
alectinib
1
abemaciclib
1
Vemurafenib
1
Taxes
1
Tamoxifen
1
STX-478
1
Radiotherapy, Intensity-Modulated
1
Nimorazole
1
Metformin
1
Letrozole
1
Imlunestrant
1
Gemcitabine
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Metformin
×
Head & Neck
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled